leisure time -WSS

leisure time

author：Wikipedia 2025-09-02 22:09:17 - browse：789

Alphabet’s life sciences company Verily has scored its first Centers for Disease Control and Prevention contract, a high profile job leaders hope will boost its brand in public health as well as its nascent wastewater surveillance business, executives told STAT.

Under the up-to-five year, $38 million contract, Verily will collect samples from hundreds of wastewater treatment centers across the country, analyze them for Covid-19 and the mpox virus at its South San Francisco lab, and return the data to CDC within 36 hours of collecting the samples. The contract is limited to those two pathogens but the company is prepared to analyze more if needed, leaders said.

The contract comes as Verily struggles to turn a profit among various disparate health care offerings, like value-based care analytics for health systems, clinical trial software and even an in-person substance use rehabilitation center in Ohio. Despite several prominent hires and a vast number of projects, the company has yet to forge a sustainable business.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Stop the failed accountable care organization experiment

focus

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Why patients can’t get everything they want on drug pricing

Gene editing the human germline: What are the risks?

Methadone treatment changes are coming. Do they go far enough?

Asbestos, a deadly carcinogen, banned by EPA

focus

leisure time

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

U.K. researchers warn about biases in medical devices, algorithms

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Intermittent fasting comes with a heart risk? Not so fast

Cancer drug shortages should be causing more outrage

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Medicare proposal to cover medical devices draws a mixed reaction

Roche’s Alnylam deal shows drug firms interested in heart drugs

Activists slam private health insurers over coverage restrictions

Stop the failed accountable care organization experiment

leisure time

Virtual Event: March of the Biosimilars

Democrats decry new health bill for going easy on private equity

Methadone treatment changes are coming. Do they go far enough?

Democrats decry new health bill for going easy on private equity

Plastic surgeons increase patient psychiatric screenings

SCOTUS questions limit to govt efforts to fight misinformation

entertainment

focus

entertainment

knowledge